EUCTR2009-011980-35-GB进行中（未招募）不适用
Multicentre, randomised, double-blind (double-dummy), active comparator-controlled, phase III study of the efficacy and safety of a single s.c. Diclofenac HPBCD 75mg/1ml injection as compared to a single i.m. Voltarol® 75mg/3ml, in the treatment of acute moderate-to-severe post-surgical pain following dental surgery (impacted 3rd molar removal).
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Out-patients of both genders.
- •2.Patients aged = 18 to = 65 years old.
- •3.Subjects able and willing to give their written consent prior to inclusion in the study.
- •4.Female subjects of childbearing potential must have a negative urine pregnancy test at screening and inclusion visit (i.e. not status post hysterectomy or tubal ligation) must be using an appropriate method of contraception according to the definition of Note of ICH M3 Guideline (implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence of vasectomised partner) and must be willing to continue using it throughout the entire study period.
- •5.Subjects must be able to comprehend the full nature and purpose of the study, including possible risks and side effects, to co-operate with the Investigator, to comply with the requirements of the entire study and to return for the required examinations.
- •Trial specific
- •6.Patients undergoing surgical extraction of a single fully or partially impacted mandibular 3rd molar requiring bone removal.
- •7.Patients experiencing moderate to severe post-operative pain, defined as a pain intensity = 50 mm (VAS), within 6 hours from end of surgery.
- •8.Pre-operative laboratory tests (haematology, blood chemistry, urinalysis), performed within 30 days before inclusion (Visit 1) in the reference ranges or without clinically significant abnormalities as judged by the Investigator.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Patients refusing to give a written informed consent.
- •2.Patients not able to understand the purposes of the study.
- •3.Patients not reliable, according to the investigator’s opinion.
- •4.Patients with major psychiatric disorders that could compromise the patient’s participation in the study.
- •5.Patients previously enrolled in this study or having used any investigational drug/device or participated in any clinical trial in the previous 3 months.
- •6.Employees of the Investigator or study centre (i.e. Principal Investigator, sub-investigator, study coordinators, other study staff, employees, or contractors of each), with direct involvement in the proposed study or other studies under the direction of that investigator and/or study centre, as well as family members of the employees or investigator.
- •7.Pregnant or breast-feeding women.
- •8.Alcohol or drug abuse within previous 12 months.
- •9.Clinically significant or unstable concurrent diseases whose sequeleae or treatment might interfere with the study evaluation parameters.
- •Trial specific
- •10.Contra-lateral lower 3rd molar extraction or any other concomitant extraction.
- •11.Surgery performed under general anaesthesia, or sedation (including nitrous oxide by inhalation).
- •12.Complications occurring during the surgical procedure or in the period before randomisation as judged by the investigator.
- •13.Acute local or systemic infection at the time of surgery that could confound the post-surgical evaluation.
- •14.Patients with clinical signs of gastritis, gastro-duodenal ulcer, GI bleeding. Other GI disturbances or disease that in the opinion of the investigator could be negatively affected by the administration of NSAIDs.
- •15.Clinical signs or history of coagulation disorders that could be negatively affected by NSAIDs administration.
- •16.Hepatic or renal impairment.
- •17.Patients with significant cardiac impairment (i.e. severe heart failure, severe ischemic heart disease) history of cerebrovascular disease (i.e. ictus), history or peripheral arterial disease, uncontrolled hypertension, (i.e. not stable = repeated measurements of systolic pressure > 160 mm Hg or diastolic pressure > 95 mm Hg, despite pharmacological treatment).
- •18.Hypersensitivity to diclofenac or other NSAIDs or to one of the study medication components.
- •19.Patients under chronic treatment with topical or systemic analgesics/NSAIDs.
研究者
相似试验
已完成
不适用
Multicentre, randomised, double-blind, parallel-group, placebo-controlled clinical trial, comparing nateglinide versus placebo to assess the efficacy and tolerability of nateglinide in patients with type two diabetes mellitusType two diabetes mellitus with more than five years of evolutionNutritional, Metabolic, EndocrineDiabetesISRCTN04296019ovartis Pharma (Novartis Farmacéutica SA) (Spain)102
进行中（未招募）
1 期
Pharmacogenomics of antiVEGF in patients with Age-Associated Macular Degeneration.age-related macular degenerationEUCTR2019-003204-12-ESConsorcio PSMAR630
进行中（未招募）
1 期
Multicentre, randomised, double-blind, parallel group confirmatory Phase III study to compare the efficacy and safety of cizolirtine citrate 300 mg bid (600 mg/d), cizolirtine citrate 400 mg bid (800 mg/d), placebo, and tolterodine 2 mg bid (4 mg/d) in the treatment of urge urinary incontinenceEUCTR2004-001116-31-ESaboratorios Dr. Esteve S.A.690
进行中（未招募）
不适用
Multicentre, randomised, double-blind, parallel group confirmatory Phase III study to compare the efficacy and safety of cizolirtine citrate 300 mg bid (600 mg/d), cizolirtine citrate 400 mg bid (800 mg/d), placebo, and tolterodine 2 mg bid (4 mg/d) in the treatment of urge urinary incontinencerge Urinary IncontinenceEUCTR2004-001116-31-GBaboratorios Dr. Esteve S.A.690
已完成
不适用
aparoscopic Excision versus OpeN Appendectomy multicentre Randomised, DOuble blind, controlled trialAcute appendicitisISRCTN42332281Sant'Orsola-Malpighi University Hospital Bologna (Italy)386